Sign inJoin waitlistJoin the waitlist

Lindsey McAlarnen

Clerkship Associate Director · University of Nebraska Medical Center College of Medicine

Credentials: · · · · · · · ·

History

University of Nebraska Medical Center College of Medicine
Present

Gynecologic Oncology
Medical College of Wisconsin - Milwaukee
2020–2023
Obstetrics and Gynecology
Loyola University Medical Center
2016–2020
The Florida State Univ Coll of Med
2012–2016

Research

Tumor Derived Extracellular Vesicles Drive T Cell Exhaustion in Tumor Microenvironment through Sphingosine Mediated Signaling and Impacting Immunotherapy Outcomes in Ovarian Cancer
Advanced Science · 2022 · 71 citations
Virtual visits among gynecologic oncology patients during the COVID-19 pandemic are accessible across the social vulnerability spectrum
Gynecologic Oncology · 2021 · First of 5 authors · Corresponding · 20 citations
Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers
Review · The Application of Clinical Genetics · 2021 · First of 3 authors · 19 citations

Denise Uyar
5 papers
Erin Bishop
5 papers
Elizabeth Hopp
4 papers · 1 as a fellow
William Bradley
4 papers
Janet Rader
3 papers
NS
Nathan Smith
2 papers · 2 as a resident
Rana Aliani
2 papers · 2 as a resident
Rebekah Summey
2 papers · 2 as a fellow
Abigail Winder
1 paper
Adam Gliniewicz
1 paper · 1 as a resident
Ann Lal
1 paper
Beth Erickson
1 paper

Clinical trials

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2034